

Entitlement Offer closing date extended to 1 December 2023

On 31 October 2023, Radiopharm Theranostics Limited (**ASX:RAD**) (**Radiopharm or Company**) announced the details of a non-renounceable entitlement offer (**Entitlement Offer**) to raise approximately \$10 million.

Under the Entitlement Offer, eligible shareholders are able to subscribe for 1 new fully paid ordinary shares in Radiopharm (**New Shares**) for every 2.35 fully paid ordinary shares in Radiopharm held as at 7pm (Sydney time) on Friday, 3 November 2023 at the issue price of \$0.07 per New Share.

Radiopharm advises that the closing date of the Entitlement Offer has been extended to 5 pm (Sydney time) on Friday, 1 December 2023 (**Extended Closing Date**). The Extended Closing Date is to ensure all eligible shareholders have an opportunity to participate in the Entitlement Offer, having regard to shareholder feedback received in relation to the Entitlement Offer.

Revised indicative timetable¹

The Extended Closing Date will have a consequential effect on the indicative timetable, including the date of allotment and issue of the New Shares under the Entitlement Offer which is now anticipated to occur on Friday, 8 December 2023.

Event	Date
Announcement of the Entitlement Offer	Tuesday, 31 October 2023
Record Date for Retail Entitlement Offer (7.00 pm AEDT)	Friday, 3 November 2023
Information Booklet and Entitlement and Acceptance Form despatched	Wednesday, 8 November 2023
Entitlement Offer opened	Wednesday, 8 November 2023
Entitlement Offer closes (5.00 pm AEDT)	Friday, 1 December 2023
New Shares quoted on a deferred settlement basis	Monday, 4 December 2023
Announcement of results of the Entitlement Offer	Friday, 8 December 2023
Allotment of New Shares under the Entitlement Offer	Friday, 8 December 2023

¹ All dates are indicative only and subject to change. The Company reserves the right to withdraw or vary the timetable without notice.

Event	Date
Despatch of holding statements for New Shares issued under the Entitlement Offer	Monday, 11 December 2023
Trading of New Shares under the Entitlement Offer commences	Monday, 11 December 2023

Electronic access

The information booklet (**Booklet**) under which the Entitlement Offer is made is available electronically at www.radiopharmtheranostics.com. The entitlement and acceptance form attached to the electronic version of the Booklet must be used within Australia or New Zealand.

Further information is available at nreo.radiopharmtheranostics.com.

For further information, please contact:

If you have questions about the Entitlement Offer, please contact the share registry, Automic Registry Services on 1300 288 664 (inside Australia) or +61 2 9698 5414 (outside Australia).

Phillip Hains
Joint Company Secretary

Important information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to in this document have not been and will not be registered under the United States Securities Act of 1933 (the 'US Securities Act'), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available.

This document may not be distributed or released in the United States.

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. Radiopharm does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.